Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial

Importance  Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective  To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants  In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, […]

A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history

Several studies have been conducted and more are underway examining psilocybin-assisted therapy as a treatment for various psychiatric conditions including depressive disorders, anxiety disorders, and alcohol use disorder. However, many studies have been limited by small sample size and have not comprehensively evaluated treatment risks outside of controlled settings. To this point, we present a case of a 30 […]

Single-dose psilocybin for a treatment-resistant episode of major depression

BACKGROUND Psilocybin is being studied for use in treatment-resistant depression. METHODS In this phase 2 double-blind trial, we randomly assigned adults with treatment resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose  of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary […]

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim […]